Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319833 | 0.85 | CYP2A6 (0.42) | CYP2A6TSHRLOXL2RAB9ACYP19A1 | |
| SCHEMBL4952656 | 0.84 | CA2 (0.58) | TSHRRAB9ACA2CA9NPC1 | |
| SCHEMBL2961510 | 0.82 | CYP2A6 (0.46) | CYP2A6TSHRLOXL2CYP19A1MAPT | |
| SCHEMBL1165338 | 0.81 | CA2 (0.44) | CA2CA9CA1 | |
| SCHEMBL9027088 | 0.80 | MAPT (0.51) | CYP2A6TSHRLOXL2RAB9ACYP19A1 | |
| SCHEMBL26449319 | 0.80 | CA2 (0.42) | RAB9ACA2CA9NPC1SMN1; SMN2 | |
| SCHEMBL29003478 | 0.80 | CYP19A1 (0.47) | CYP2A6TSHRLOXL2RAB9ACYP19A1 | |
| SCHEMBL7417122 | 0.80 | TSHR (0.47) | CYP2A6TSHRLOXL2CYP19A1MAPT | |
| SCHEMBL1228846 | 0.80 | GLA (0.48) | MAPTMAOB | |
| SCHEMBL2962876 | 0.78 | TSHR (0.50) | CYP2A6TSHRLOXL2CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| WO-2011070588-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | CYP2A6 1425/4885TSHR 4705/4885LOXL2 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.